CervoMed Inc.

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders. The company's primary drug candidate is neflamapimod, an investigational, orally administered small-molecule drug. Neflamapimod is designed to cross the blood-brain barrier and selectively inhibit the enzyme p38α, which is a key contributor to neuroinflammation and synaptic dysfunction. By targeting these critical disease processes, neflamapimod aims to reverse synaptic dysfunction, improve neuron health, and potentially slow or prevent disease progression. Neflamapimod is currently undergoing clinical development for several conditions. Its lead indication is the treatment of Dementia with Lewy Bodies (DLB). It is also being developed for non-fluent variant primary progressive aphasia (nfvPPA), Rett Syndrome (RAS), and Amyotrophic Lateral Sclerosis (ALS). The company's approach emphasizes reducing the impact of neuroinflammation, which is considered a significant factor in the development of degenerative brain diseases. Chronic activation of p38α in individuals with certain neurodegenerative diseases is thought to impair neuronal communication through synapses, leading to a decline in cognitive and motor abilities. CervoMed Inc. believes that inhibiting p38α activity could reverse early clinical progression and delay permanent synaptic dysfunction and neuron death. The company considers itself a leader in developing a treatment for DLB, a condition with no approved therapies in the US or European Union. Neflamapimod is reported to be the only clinical drug candidate that has demonstrated statistically significant improvements on clinical endpoints and a biomarker of neurodegeneration in both a Phase 2a and Phase 2b clinical trial.